CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 37 enrolled
Drug / intervention
tofacitinib 5mg po biddrug
Likely dose
tofacitinib 5mg po bidfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02321930
NCT02321930Phase 4Completed
CompareCT.gov

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

University of California, Los Angeles·interventional·Posted Dec 22, 2014·Updated Mar 19, 2019

In Brief

A Phase 4 clinical trial evaluating tofacitinib 5mg po bid for Rheumatoid Arthritis. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 22, 2014
Enrollment StartFeb 16, 2016
Primary CompletionSep 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.5 years ago

Interventions

tofacitinib 5mg po biddrug